Tristel Valuation Multiples

Tristel Overview

About Tristel

Tristel PLC’s business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.

Founded

2003

HQ

Employees

265

Website

tristel.com

Sectors

Medical Supplies

Financials (LTM)

Revenue: $68M

EBITDA: $19M

EV

$240M

Valuation Multiples

Multiples.vc

Start free trial

Tristel Financials

Tristel reported last 12-month revenue of $68M and EBITDA of $19M.

In the same LTM period, Tristel generated $55M in gross profit, $19M in EBITDA, and $11M in net income.

Tristel P&L

In the most recent fiscal year, Tristel reported revenue of $63M and EBITDA of $17M.

Tristel expects next 12-month revenue of XXX and NTM EBITDA of XXX

Tristel Stock Performance

Tristel has current market cap of $250M, and enterprise value of $240M.

Tristel's stock price is $5.21.

Tristel Valuation Multiples

Tristel trades at 3.5x EV/Revenue multiple, and 12.9x EV/EBITDA.

Tristel Financial Valuation Multiples

As of April 20, 2026, Tristel has market cap of $250M and EV of $240M.

Equity research analysts estimate Tristel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tristel has a P/E ratio of 22.7x.

Tristel Margins & Growth Rates

Tristel's revenue in the last 12 month grew by 10%.

Tristel's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Tristel's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tristel's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Tristel Public Comps

See public comps and valuation multiples for other Medical Supplies comps.

Tristel M&A Activity

Tristel acquired XXX companies to date.

Last acquisition by Tristel was on XXXXXXXX, XXXXX. Tristel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Tristel Investment Activity

Tristel invested in XXX companies to date.

Tristel made its latest investment on XXXXXXXX, XXXXX. Tristel invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).